Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

69.91 +1.42 (+2.07%)
Streaming Delayed Price Updated: 12:46 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,320,869
Open 71.55
Bid (Size) 69.90 (2)
Ask (Size) 69.91 (1)
Prev. Close 68.49
Today's Range 69.56 - 72.18
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir. 
Via Benzinga

Performance

YTD
-16.02%
-16.02%
1 Month
+3.89%
+3.89%
3 Month
-4.36%
-4.36%
6 Month
-11.43%
-11.43%
1 Year
-9.93%
-9.93%

More News

Read More
Pre-Market Movers - June 21, 2024
Via Talk Markets
Defying the Norms: 3 High P/E Stocks With Room to Run
Via InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
Via Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
What 8 Analyst Ratings Have To Say About Gilead Sciences
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
Via Investor's Business Daily
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Via Benzinga
Topics Death
Exposures Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
Via The Motley Fool
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.